Ceruloplasmin Is an Endogenous Inhibitor of Myeloperoxidase

被引:107
|
作者
Chapman, Anna L. P. [1 ]
Mocatta, Tessa J. [1 ]
Shiva, Sruti [3 ]
Seidel, Antonia [2 ]
Chen, Brian [1 ]
Khalilova, Irada [1 ]
Paumann-Page, Martina E. [1 ]
Jameson, Guy N. L. [2 ]
Winterbourn, Christine C. [1 ]
Kettle, Anthony J. [1 ]
机构
[1] Univ Otago, Ctr Free Rad Res, Dept Pathol, Christchurch 8140, New Zealand
[2] Univ Otago, Dept Chem, Dunedin, New Zealand
[3] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15261 USA
关键词
INFLAMMATORY-BOWEL-DISEASE; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; CATALYZED OXIDATION; COMPOUND-I; PROTEIN; KINETICS; ASSOCIATION;
D O I
10.1074/jbc.M112.418970
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloperoxidase is a neutrophil enzyme that promotes oxidative stress in numerous inflammatory pathologies. It uses hydrogen peroxide to catalyze the production of strong oxidants including chlorine bleach and free radicals. A physiological defense against the inappropriate action of this enzyme has yet to be identified. We found that myeloperoxidase oxidized 75% of the ascorbate in plasma from ceruloplasmin knock-out mice, but there was no significant loss in plasma from wild type animals. When myeloperoxidase was added to human plasma it became bound to other proteins and was reversibly inhibited. Ceruloplasmin was the predominant protein associated with myeloperoxidase. When the purified proteins were mixed, they became strongly but reversibly associated. Ceruloplasmin was a potent inhibitor of purified myeloperoxidase, inhibiting production of hypochlorous acid by 50% at 25 nM. Ceruloplasmin rapidly reduced Compound I, the FeV redox intermediate of myeloperoxidase, to Compound II, which has Fe-IV in its heme prosthetic groups. It also prevented the fast reduction of Compound II by tyrosine. In the presence of chloride and hydrogen peroxide, ceruloplasmin converted myeloperoxidase to Compound II and slowed its conversion back to the ferric enzyme. Collectively, our results indicate that ceruloplasmin inhibits myeloperoxidase by reducing Compound I and then trapping the enzyme as inactive Compound II. We propose that ceruloplasmin should provide a protective shield against inadvertent oxidant production by myeloperoxidase during inflammation.
引用
收藏
页码:6465 / 6477
页数:13
相关论文
共 50 条
  • [41] The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture
    Teng, Nathaniel
    Maghzal, Ghassan J.
    Talib, Jihan
    Rashid, Imran
    Lau, Antony K.
    Stocker, Roland
    REDOX REPORT, 2017, 22 (02) : 51 - 73
  • [42] Ceruloplasmin and antioxidative enzymes in pre-eclampsia
    Nikolic, Aleksandra
    Cabarkapa, Velibor
    Mikic, Aleksandra Novakov
    Jakovljevic, Ana
    Stosic, Zoran
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2016, 29 (18) : 2987 - 2993
  • [43] Myeloperoxidase
    Klebanoff, SJ
    PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1999, 111 (05) : 383 - 389
  • [44] Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease
    Kimak, Elzbieta
    Zieba, Bartosz
    Duma, Dariusz
    Solski, Janusz
    LIPIDS IN HEALTH AND DISEASE, 2018, 17
  • [45] Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection
    Ramachandra, Chrishan J. A.
    Ja, K. P. Myu Mai
    Chua, Jasper
    Cong, Shuo
    Shim, Winston
    Hausenloy, Derek J.
    ANTIOXIDANTS & REDOX SIGNALING, 2020, 32 (15) : 1135 - 1149
  • [46] Imaging Myeloperoxidase Activity in Cardiovascular Disease
    Ronald J.A.
    Current Cardiovascular Imaging Reports, 2011, 4 (1) : 24 - 31
  • [47] In vitro activation of dibromoacetonitrile to cyanide by myeloperoxidase
    Al-Abbasi, Fahad A.
    TOXICOLOGY AND INDUSTRIAL HEALTH, 2016, 32 (08) : 1478 - 1485
  • [48] Myeloperoxidase expression in human colonic mucosa is related to systemic oxidative balance in healthy subjects
    Mancini, Stefano
    Mariani, Francesco
    Sena, Paola
    Benincasa, Marta
    Roncucci, Luca
    REDOX REPORT, 2017, 22 (06) : 399 - 407
  • [49] Triazolopyrimidines identified as reversible myeloperoxidase inhibitors
    Duclos, Franck
    Abell, Lynn M.
    Harden, David G.
    Pike, Kristen
    Nowak, Kimberly
    Locke, Gregory A.
    Duke, Gerald J.
    Liu, Xiaoqin
    Fernando, Gayani
    Shaw, Scott A.
    Vokits, Benjamin P.
    Wurtz, Nicholas R.
    Viet, Andrew
    Valente, Meriah N.
    Stachura, Sylwia
    Sleph, Paul
    Khan, Javed A.
    Gao, Ji
    Dongre, Ashok R.
    Zhao, Lei
    Wexler, Ruth R.
    Gordon, David A.
    Kick, Ellen K.
    MEDCHEMCOMM, 2017, 8 (11) : 2093 - 2099
  • [50] Microbial--derived indoles inhibit neutrophil myeloperoxidase to diminish bystander tissue damage
    Alexeev, Erica E.
    Dowdell, Alexander S.
    Henen, Morkos A.
    Lanis, Jordi M.
    Lee, J. Scott
    Cartwright, Ian M.
    Schaefer, Rachel E. M.
    Ornelas, Alfredo
    Onyiah, Joseph C.
    Vogeli, Beat
    Colgan, Sean P.
    FASEB JOURNAL, 2021, 35 (05)